BIAL

Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 50 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. Our strategic areas are Innovation, Internationalisation and Quality.Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular.BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, commercialized in Europe and already approved in USA, Japan and South Korea. . The company expects to introduce new medicines to the market over the next few years, strengthening its international presence.The company headquarters are located in Portugal. BIAL has also facilities in Spain, Germany, United Kingdom, Italy, Switzerland, Mozambique, Angola, Panama and Ivory Coast.BIAL Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA). BIAL Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award in Biomedicine, the Prémio BIAL de Medicina Clínica and Scientific Research Grants, well recognized worldwide.For more information, please visit: www.bial.com For issues of safety or others related to product quality, please contact: [email protected]